Kidney Week 2019 — Canagliflozin reduces the risk of renal events in T2D


  • Marielle Fares, Pharm.D.
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with type 2 diabetes (T2D) and kidney disease, canagliflozin reduced the risk of renal failure and cardiovascular events compared with placebo.

Why this matters

  • Type 2 diabetes increases the risk of kidney failure.
  • Studies of sodium-glucose transporters in cardiovascular disease showed an improvement in renal outcomes in patients with T2D.

Study design

  • Randomized, double-blind trial of 4401 patients with T2D and albuminuric chronic kidney disease to receive canagliflozin 100 mg daily or placebo.
  • Patients had an estimated glomerular filtration rate (eGFR) of 30 to 2 and albuminuria (albumin to creatinine ratio >300-5000 mg/g) and were treated with renin-angiotensin system blockade.
  • Primary endpoint was a composite of end-stage kidney disease (dialysis, transplantation, or sustained eGFR of 15 mL/minute/1.73 m2), doubling of serum creatinine, or death from renal or cardiovascular causes.

Key results

  • At the follow-up of 2.62 years, there was a decrease in the relative risk of the composite of end-stage kidney disease, doubling of the creatinine level, death from renal causes in the canagliflozin group by 34% (HR 0.66; 95% CI, 0.53-0.81; P<.001 and in the relative risk of end-stage kidney disease group by ci p=".002).</li">
  • There was a lower risk of cardiovascular death, myocardial infarction, or stroke, and hospitalization for heart failure (HR 0.61, 95% CI, 0.47-0.80, P<.001>

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit